Tigercub khá busy. Làm việc suốt ngày. Sắp tốt nghiệp Huy a. Đọc thì ok nhưng mà dich ra thì không có thời gian.

Tóm tắt là:

Đây là một thử nghiệm vaccine biến đổi gen chống virus HIV tại Thuy Điễn. Người ta sử dụng một đaọn DNA của virus nay để làm vaccin. Kết quả ban đâu cho thấy 90% hiệu quả đáp ứng miễn dịch. Một kết quả tốt chưa từng thấy đối với laọi vaccine này. Kết quả đã trình bày tại hội nghị khoa học nghiên cứu về vaccine phòng HIV vào ngày 29/8 vừa qua tại Amsterdam, Hàlan.

Giai đoạn tiếp theo ngừơi ta sẽ thử nghiệm tại Tanzania, Châu Phi vào mùa thu năm nay.

Nghiên cứu này do giáo sư KI professors Gunnel Biberfeld và Britta Wahren chiu trách nhiệm.

Thông tin về các nghiên cứu và thử nghiệm HIV mới được các bạn bè năm châu gửi :

http://www.sabcnews.com/south_africa/health/0,2172,137166,00.html

http://communications.uwo.ca/western_news/story.html?listing_id=22063

http://www.hamiltonspectator.com/NASApp/cs/ContentServer?pagename=hamilton/Layout/Article_Type1&c=Article&cid=1161121814723&call_pageid=1020420665036&col=1014656511815

Radioactive Antibody Therapy Shows Promise

By Tim Horn, Senior Writer & Editor, AIDSmeds.com

Using a new strategy featuring radioactive antibodies, researchers at the Albert Einstein College of Medicine of Yeshiva University in Bronx, New York, have successfully targeted and destroyed HIV-infected CD4 cells in laboratory experiments involving mice.

"This study supports the idea that radiation might help in treating people infected with HIV," says Dr. Arturo Casadevall, Chair of the Department of Microbiology and Immunology and a senior author of the study, which appears in the November issue of the online journal PloS Medicine. "More broadly, this work introduces a new approach for treating the many viral infections, from hepatitis C to Ebola, in which viral proteins are expressed on the surface of infected cells."

The Einstein researchers used a technique called radioimmunotherapy, in which radioactive molecules (radioisotopes) are piggy-backed onto antibodies. Once injected into the body, the antibodies seek out specific proteins and the radioisotopes destroy the cells to which the protein is attached.

Radioimmunotherapy is an accepted treatment for several types of cancer, including non-Hodgkin's lymphoma. But at Einstein, investigators have been looking at the possibility of using it to treat various infectious diseases.

In a series of animal studies beginning in 2001, the Einstein researchers have successfully used radioimmunotherapy against a variety of disease-causing infections, including those responsible for cryptococcal meningitis and bacterial pneumonia. With these infections, radioimmunotherapy is used to directly target the disease-causing microorganisms. In the case of HIV, the treatment is used to target HIV-infected CD4 (T4) cells in the body.

In this study, antibodies targeting gp41 – one of HIV's proteins that can be found on the surface of CD4 cells the virus has infected – were used. The researchers tagged these antibodies with two different radioisotopes, bismuth 213 and rhenium 188.

To test the therapy, the researchers first injected HIV-infected CD4 cells into the spleens of immune-deficient mice. One hour later, the mice were injected with the radioactive antibodies.

Three days after treatment, the researchers measured the number of HIV-infected cells in the spleens. Compared with control mice treated with antibodies without radioisotopes, the number of HIV-infected CD4 cells in the treated mice was significantly reduced.

"Today's antiretroviral drug therapies can inhibit the multiplication of HIV and help prevent HIV from infecting additional cells," says Dr. Harris Goldstein, Director of the Center for AIDS Research at Einstein. "But we currently have no way of eliminating the HIV-infected cells that make these infections chronic. The novelty of this technique is that it targets the cells infected by HIV, which act as ‘factories' for making more of the virus. So if we could eradicate all the HIV-infected cells in a patient – which would likely require a combination of therapies – then we could start to think about curing HIV-infected patients."

Dr. Goldstein, also a senior author of the study, notes that radioimmunotherapy might be particularly useful for people newly exposed to HIV. "Studies show that giving [HIV treatment] to people within 24 hours of exposure to HIV can prevent infection from developing," he says. "But if several days have passed, the virus is able to infect enough cells to cause a chronic HIV infection. By combining standard treatment with radioimmunotherapy, we may be able to prevent lifelong infection in these people by eliminating those initially infected cells."

Clinical trials using radioimmunotherapy for treating HIV infection are now being planned.


link: http://www.aidsmeds.com/news/am20061108.html

Chắc TIGER sẽ dịch sơ lược cho các bạn!

Chào cả  nhà,

Hôm nay thông tin về HIV vaccine tiếp tục được bạn HUY cập nhật và gửi cho HUY!

Nguồn :http://www.tcgnews.com/santiagotimes/index.php?nav=story&story_id=12528&topic_id=15
 TIN VỀ THỬ NGHIỆM HIV TẠI  CHI LÊ
Một nghiên cứu tại CHILE cho thông tin rất khả quan về thử nghiệm thuốc MK-0518, thuốc này có DNA và được  tiêm vào các tế bào white blood cells, sau đó kết quả cho biết :
- Nồng độ HIV trong cơ thể bệnh nhân giảm 98% .
-Không có tác dụng phụ gì đáng kể.
-Và sẽ sắp chuyển qua giai đoạn 3


Hy vọng sẽ có mặt tại thị trường trong 2 năm tới!

Và, sẽ có mặt tại các tiệm thuốc ở VN trong 2,5 năm tới!

Và sẽ không còn cái diễn đàn này nữa( vì HIV kô là fatal nữa ) trong 3 năm tới!

Thân!


REVOLUTIONARY NEW AIDS DRUG TESTED IN CHILE

(December 18, 2006) A study conducted in Chile to test a new drug targeting the HIV virus has showed encouraging results in patients. Now, drug company Merck Sharp & Dohme (MSD) is beginning a new study to test an HIV vaccine, and it looks as though Chile will be involved.

The initial study was part of a larger drug trial being conducted by MSD prior to presenting the product for approval by the U.S. Food and Drug Administration (FDA). Although the Chilean portion of the project was small, only involving 10 patients, the results were staggering.

MSD’s new drug MK-0518 works to inhibit an enzyme used by HIV to invade the immune system, which it does by injecting its DNA into white blood cells. In layman’s terms, this drug prevents HIV from replicating itself in the body.

In the Chilean portion of the study, the drug resulted in an average 98 percent decrease in the presence of HIV in patients.

The Chilean patients involved in the drug trial all saw a reduction in the virus’s presence almost to the point of nonexistence. U. de Chile immunologist Dr. Alejandro Afani explained that study participants “have been able to reduce the quantity of the virus in their bodies to undetectable levels, with good response in the lymphocytes and almost no adverse side effects. . . . This is a great source of hope for those who are resistant to other drugs. I believe that in two years this product will be on the market.”

The new treatment is the latest breakthrough in HIV/AIDS care and comes just months after the FDA approval of the one-a-day Atripla pill. Atripla replaces a three-drug combination that most HIV/AIDS patients were taking before, and which caused complications in treatment, especially in poorer countries, because of its strict dosage schedule.

MSD’s newest project is an HIV vaccine that is in the second stage of drug trials. Dr. Afani said, “We are in negotiations and Chile may be involved in the trial’s third phase.”

SOURCE: LA TERCERA
By Laurel Bernstein ([email protected])

Cristian Rodriguez